Literature DB >> 11809535

Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells.

Tomomi Ikegawa1, Hisakazu Ohtani, Noriko Koyabu, Motoharu Juichi, Yukiko Iwase, Chihiro Ito, Hiroshi Furukawa, Mikihiko Naito, Takashi Tsuruo, Yasufumi Sawada.   

Abstract

We investigated the effects of natural flavones, quercetin and morin, and their pentamethyl, pentaethyl, pentapropyl, pentabutyl and pentaallyl ethers, on the function of P-glycoprotein (P-gp) assessed by an increase in the uptake of [3H]vincristine by human myelogenous leukemia (K562) cells and adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Pentamethyl, pentaethyl, pentapropyl and pentaallyl ethers of morin and quercetin (20 microM) all increased the uptake of [3H]vincristine by K562/ADM cells, while quercetin, morin and their pentabutyl ethers had no effect. Pentamethylquercetin, pentaallylquercetin and pentaethylmorin remarkably increased the uptake of [3H]vincristine by K562/ADM cells by 10.6, 10.8 and 14.4-fold, respectively. These inhibitory potencies for P-gp were more potent than typical P-gp inhibitors, cyclosporine A and verapamil. Taking into consideration that these flavonoid derivatives possess antitumor promoter activity, they may become candidates of effective multidrug resistance-reversing agents in cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11809535     DOI: 10.1016/s0304-3835(01)00761-3

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

Review 1.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

3.  Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways.

Authors:  Wen Jiang; Ming Hu
Journal:  RSC Adv       Date:  2012-09-21       Impact factor: 3.361

4.  Morin (3,5,7,2',4'-Pentahydroxyflavone) abolishes nuclear factor-kappaB activation induced by various carcinogens and inflammatory stimuli, leading to suppression of nuclear factor-kappaB-regulated gene expression and up-regulation of apoptosis.

Authors:  Sunil K Manna; Rishi S Aggarwal; Gautam Sethi; Bharat B Aggarwal; Govindarajan T Ramesh
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

5.  Pentamethylquercetin generates beneficial effects in monosodium glutamate-induced obese mice and C2C12 myotubes by activating AMP-activated protein kinase.

Authors:  J Z Shen; L N Ma; Y Han; J X Liu; W Q Yang; L Chen; Y Liu; Y Hu; M W Jin
Journal:  Diabetologia       Date:  2012-03-14       Impact factor: 10.122

6.  Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin.

Authors:  Dominik Bieg; Daniel Sypniewski; Ewa Nowak; Ilona Bednarek
Journal:  Arch Gynecol Obstet       Date:  2018-09-28       Impact factor: 2.344

7.  Chemotherapy and dietary phytochemical agents.

Authors:  Katrin Sak
Journal:  Chemother Res Pract       Date:  2012-12-20

Review 8.  South Asian Medicinal Compounds as Modulators of Resistance to Chemotherapy and Radiotherapy.

Authors:  N Rajendra Prasad; Ganesan Muthusamy; Mohana Shanmugam; Suresh V Ambudkar
Journal:  Cancers (Basel)       Date:  2016-03-05       Impact factor: 6.639

9.  Perturbation of the lipid phase of a membrane is not involved in the modulation of MRP1 transport activity by flavonoids.

Authors:  Olga Wesołowska; Andrzej B Hendrich; Barbara Łaniapietrzak; Jerzy Wiśniewski; Joseph Molnar; Imre Ocsovszki; Krystyna Michalak
Journal:  Cell Mol Biol Lett       Date:  2008-11-19       Impact factor: 5.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.